1993: 5 of a total of 7 (72%) patients achieved total eradication of their cancer (R/R AML), page-26

  1. 3,320 Posts.
    lightbulb Created with Sketch. 11956
    Yes you have picked up on a very important point @Aqua65 - bone marrow transplants have really advanced over the last 30 years. Back when Bisantrene was on the market you could only do a bone marrow transplant (called a stem cell transplant now days) if you had a perfect match donor - basically a brother or sister. Even if you had a perfect match donor then your chance of dying in the first few months was really high - about 30%. These days they can do stem cell transplants with partial matches (for example they can match you to one of your parents) and the death rate from the transplant has come down to around 3%.

    Cytarabine is not a nice drug to take (especially at high doses) and it has a lot very nasty side effects. The big advantage of cytarabine in AML is it synergies with the commonly used anthracyclines (daunorubicin, Idarubicin, etc). It can also be used in some relapsed patients, and at low doses as a palliative treatment for patients too unfit (ill) to handle high intensity chemo.

    Yes it has been one of the two backbones of treating AML for the past 50 years and it is used in all patients fit enough to handle chemo. I think it will continue to be used for a long time to come especially given how cheap it is.


 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.16
Change
-0.005(0.43%)
Mkt cap ! $200.6M
Open High Low Value Volume
$1.20 $1.20 $1.15 $15.85K 13.65K

Buyers (Bids)

No. Vol. Price($)
2 2345 $1.16
 

Sellers (Offers)

Price($) Vol. No.
$1.18 459 1
View Market Depth
Last trade - 14.30pm 15/07/2025 (20 minute delay) ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.